Molecular docking analysis of antimicrobial peptides with the CXCL1 protein target for colorectal cancer

Antimicrobial peptides (AMPs) play a prominent role in drug discovery due to the rapid increase in drug resistant infections. Hence, we report the molecular docking analysis of antimicrobial peptides MREEKKERKRD and MVQGAKRGGRLHRV with the target protein CXCL1 in the context of colorectal cancer for further consideration in drug discovery.


Background:
Colorectal cancer (CRC) is the third most prevalent cancer in the world and causes second mortality rate [1]. Worldwide around 1.4 million people have been identified CRC in the year 2012 [2]. Globally, the incidence of colorectal cancer varies with the highest incidence rates in Australia and New Zealand, Europe and North America and lowest rates recorded in Africa and Asia [3]. Several factors have been shown in individuals at risk to CRC which includes age, presence of polyps, bowel diseases, life style, obesity, poor diet, smoking, alcohol consumption and genetic background have been shown 80% risk of colorectal cancer causes [4]. The most common tumor location in CRC is in the proximal colon, followed by rectum and distal colon [5]. AMPs have a wide spectrum of activities towards different type of organisms such as bacteria, viruses, fungi and mammalian cells, however the molecular mechanism is not yet understood [6]. Conventional treatments like radiation, chemotherapy and surgery are associated with side effects and toxicity, which affects the quality of life. Also, cancer cells are tending to develop resistance against radio and chemotherapy

Materials and Methods:
All the computational work has been carried out on Dell Optiplex 380 Intel (R) Core (TM) i-2400 CPU @ 3.10 GHz processor.

Retrieval of Biological Data:
The 3D structure of the chemokines (C-X-C motif) ligand 1 (CXCL1) was not available in Protein Data Bank. The structure of the CXCL1 was modelled using I-TASSER (Iterative Threading Assembly Refinement) standalone tool [9] with the available amino acid sequence (P09341) from UniProtKB [10]. The best model was taken for further studies. It was validated using the Ramachandran plot generated using the RAMPAGE server [11]. The Antimicrobial peptides were downloaded from NCBI (National Center for Biotechnology Information) and developed the structure by using a molecular graphics tool, PyMOL [12].
Protein structure preparation: The protein structure was prepared using protein preparation wizard present in the Maestro

Toxicity prediction:
ADMET properties of Antimicrobial peptides were calculated by using the QikProp module [17] in Schrodinger suite. QikProp generates physically relevant descriptors and overall ADME properties and drug-likeness parameter, which were used to assess the drug ability of the compounds as shown in (Table 1).   (Table 2) and the same CXCL1 protein with available small molecule drugs interaction were described in (Table 3).

Results and Discussion:
Computational docking studies have proven to be useful in the drug discovery and development of small molecule drugs.
©Biomedical Informatics (2021) Similarly there is a rapid growth made in the field of peptide therapeutics. The antimicrobial cleaved peptide sequence with the length of 5-12 amino acids was downloaded and the sequence was converted into structure by using PyMOL. The antimicrobial peptides were screened based on the ADMET toxicity prediction. Those peptides with the CXCL1 target were subjected to molecular docking analysis to find out the best lead drug for colorectal cancer. This study focused on designing a novel peptide drug for colorectal cancer. The binding affinity of the CXCL1 against antimicrobial peptides was determined by molecular docking studies in order to find a lead drug molecule. Computational docking studies identify the top ranked binding affinity of the given antimicrobial peptides with CXCL1 target. The protein-peptides complex got the highest docking score of -57.848, -55.765 shown in (Figure 1, 2 (Table 3). These results depicts that the target (CXCL1) with the antimicrobial peptide (MREEKKERKRD) complex will acts as a novel lead drug for colorectal cancer.     Open access